Friday, 16 October 2026European Markets

SELVAAG BOLIG And IMMOBEL Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(VIANEWS) - SELVAAG BOLIG (SBO.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Real Estate sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SELVAAG BOLIG (SBO.OL) kr32.40 12.38% 14.93%
IMMOBEL (IMMO.BR) €37.25 8.45% 1.79%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SELVAAG BOLIG (SBO.OL)

12.38% Forward Dividend Yield and 14.93% Return On Equity

Selvaag Bolig ASA, a housing development company, engages in the development, construction, and sale of residential properties in Greater Oslo, Bergen, Stavanger, Trondheim, and Stockholm. The company also offers project management services. Selvaag Bolig ASA was incorporated in 2008 and is headquartered in Oslo, Norway. Selvaag Bolig ASA is a subsidiary of Selvaag AS.

Earnings Per Share

As for profitability, SELVAAG BOLIG has a trailing twelve months EPS of kr3.93.

PE Ratio

SELVAAG BOLIG has a trailing twelve months price to earnings ratio of 8.24. Meaning, the purchaser of the share is investing kr8.24 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.93%.

Moving Average

SELVAAG BOLIG's value is under its 50-day moving average of kr34.43 and below its 200-day moving average of kr33.16.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SELVAAG BOLIG's EBITDA is 1.52.

More news about SELVAAG BOLIG.

2. IMMOBEL (IMMO.BR)

8.45% Forward Dividend Yield and 1.79% Return On Equity

Immobel SA engages in the real estate development business in Belgium, Luxemburg, France, Germany, Poland, and Spain. The company undertakes office, residential, and retail projects, as well as develops real estate projects for living, working, and recreational activities. It also provides project management and leasing services. The company was formerly known as Allfin NV and changed its name to Immobel SA in June 2016. The company was incorporated in 1863 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, IMMOBEL has a trailing twelve months EPS of €1.08.

PE Ratio

IMMOBEL has a trailing twelve months price to earnings ratio of 34.49. Meaning, the purchaser of the share is investing €34.49 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.79%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Apr 24, 2023, the estimated forward annual dividend rate is 3.05 and the estimated forward annual dividend yield is 8.45%.

Volatility

IMMOBEL's last week, last month's, and last quarter's current intraday variation average was a negative 1.51%, a negative 0.30%, and a positive 1.57%.

IMMOBEL's highest amplitude of average volatility was 1.70% (last week), 1.44% (last month), and 1.57% (last quarter).

Moving Average

IMMOBEL's worth is way under its 50-day moving average of €42.19 and way under its 200-day moving average of €46.07.

More news about IMMOBEL.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com